United Therapeutics' Ralinepag Shows 55% Risk Reduction in PAH Study
Event summary
- Ralinepag reduced risk of clinical worsening by 55% in PAH patients vs. placebo (HR 0.45, p<0.0001).
- Study included 687 patients, 80% on dual background therapy, 70% WHO/NYHA FC II at baseline.
- Secondary endpoints (6MWD, NT-proBNP) also showed statistically significant improvements.
- FDA NDA submission planned for second half of 2026.
The big picture
United Therapeutics' positive phase 3 results for ralinepag represent a significant advancement in PAH treatment, potentially offering a more convenient oral alternative to existing therapies. The study's robust efficacy data positions ralinepag as a potential game-changer in a market with persistent unmet needs. The company's long-standing focus on prostacyclin-based science gives it a competitive edge in this niche therapeutic area.
What we're watching
- Regulatory Pathway
- Whether the FDA will require additional data beyond the ADVANCE OUTCOMES results for approval.
- Market Positioning
- How ralinepag will compete with existing PAH therapies, particularly its once-daily oral formulation.
- Commercialization Timing
- The pace at which United Therapeutics can bring ralinepag to market if approved, given the planned NDA submission.
Related topics